Drug Safety Information for NOVOLIN 70/30 (Insulin recombinant human; insulin susp isophane recombinant human)

Number of FDA Adverse Event Reports by Patient Age for NOVOLIN 70/30

Total Reports Filed with FDA: 26760*

* Reports for drugs with the same active ingredients have been aggregated in this analysis: Insulin recombinant human; insulin susp isophane recombinant human (Novolin 70/30, Humulin 50/50, Humulin 70/30, Humulin 70/30 pen)

Charts are based on 26760 reports filed with the FDA between 2004 and June 2015.

Adverse Event Reports are submitted to the FDA by pharmaceutical companies (mandatory reporting is required by manufacturers, distributors, or importers), health care providers such as doctors (voluntary reporting), and by patients themselves (voluntary reporting). More Information on FDA MedWatch (FDA Safety Information and Adverse Event Reporting Program)Voluntary reporting takes place under the FDA's MedWatch program, where health care professionals and consumers submit reports to FDA when they find a problem with a drug, medical device, biologic, or other FDA-regulated product. An adverse event is any undesirable experience or extreme side effect associated with the use of a medical product. Adverse events include: death, life threatening event, hospitalization, disability or permanent damage, congenital anomaly or birth defect, medical product use requiring a surgical or other intervention, or other serious medical situation believed to be caused by the drug.